JK 50561
Alternative Names: 50561; Inforget; JK-50561Latest Information Update: 22 Aug 2023
At a glance
- Originator Beijing Joekai Biotechnology
 - Class Antidementias; Behavioural disorder therapies; Small molecules; Vascular disorder therapies
 - Mechanism of Action Rac1 GTP binding protein inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Phase II Alzheimer's disease
 - Preclinical Amnesia; Brain disorders; Vascular dementia
 
Most Recent Events
- 22 Aug 2023 Beijing Joekai Biotechnology plans phase-IIa trial in Vascular dementia in 3Q of 2024 (Beijing Joekai Biotechnology pipeline, August 2023)
 - 22 Aug 2023 Beijing Joekai Biotechnology plans phase-III trial in Alzheimer's disease in 4Q of 2024 (Beijing Joekai Biotechnology pipeline, August 2023)
 - 24 Apr 2023 Preclinical trials in Amnesia in China (unspecified route) prior to April 2023 (Beijing Joekai Biotechnology pipeline, April 2023).